Shield Therapeutics financials at a glance

+ Portfolio

The revenue of Shield Therapeutics is reported as 0.01046 billion Pounds in the fiscal year 2023. The earnings were -0.04 Pounds per share in 2023, which was 63.64 higher than 2022. And about -0.03053 billion Pounds are reported as free cash flow in the financials of Shield Therapeutics 2023. No dividends were paid to the shareholders of the Shield Therapeutics stock AIM:STX in the financial year 2023.

£10.46M

Revenue

£-0.04

Earnings Per Share

30.78%

Gross Margin %

£-27.78M

Free Cash Flow

Revenue

10.46

Earnings Per Share

-0.04

Gross Margin %

30.78

Free Cash Flow

-27.78

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017
Rev.	Revenue	N/A	£10.46M	£4.47M	£1.52M	£10.39M	£0.72M	£11.88M	£0.64M
GM %	Gross Margin %	44.77%	30.78%	44.71%	35.48%	86.96%	32.55%	97.38%	75.67%
OM	Operating Margin	0.00%	-,239.44%	0.00%	0.00%	-20.74%	0.00%	-43.42%	0.00%
EPS	Earnings Per Share	£-0.10	£-0.04	£-0.11	£-0.09	£-0.02	£-0.08	£-0.02	£-0.15
Div.	Dividends	N/A	£0.00	£0.00	£0.00	£0.00	£0.00	£0.00	£0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	628.82M	259.39M	215.89M	117.62M	117.19M	116.43M	116.43M
OCF	Operating Cash Flow	N/A	£-27.36M	£-18.11M	£-16.74M	£-1.40M	£-4.07M	£-0.18M	£-16.15M
FCF	Free Cash Flow	N/A	£-27.78M	£-18.38M	£-17.11M	£-1.42M	£-5.42M	£0.00M	£-19.32M
FCFS	Free Cash Flow Per Share	£-0.06	£-0.06	£-0.08	£-0.10	£-0.01	£-0.05	£-0.03	£-0.17

Shield Therapeutics financials at a glance

Financials

Discover